Receptor occupancy theory-based analysis of interindividual differences in antiemetic effects of 5-HT3 receptor antagonists

International Journal of Clinical Oncology

Volumn 14, Issue 6, 2009, Pages 518-524

  Ayuhara, Hideaki ^a   Takayanagi, Risa ^a   Okuyama, Kiyoshi ^b   Yoshimoto, Koichi ^b   Ozeki, Takeshi ^a   Yokoyama, Haruko ^a   Yamada, Yasuhiko ^a  

^a TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

5 HT3 receptor antagonist; 5 HT3 receptor occupancy; Antiemetic effect; Interindividual difference

Indexed keywords

AZASETRON; GRANISETRON; INDISETRON; ONDANSETRON; RAMOSETRON; TROPISETRON;

ANTIEMETIC ACTIVITY; ARTICLE; CHEMOTHERAPY; DRUG EFFECT; HUMAN; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; VOMITING;

ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZIMIDAZOLES; BICYCLO COMPOUNDS, HETEROCYCLIC; DRUG ADMINISTRATION SCHEDULE; GRANISETRON; HUMANS; INDOLES; MODELS, THEORETICAL; ONDANSETRON; OXAZINES; RECEPTORS, SEROTONIN, 5-HT3; TREATMENT OUTCOME; VOMITING;

EID: 72949084897     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-009-0912-5     Document Type: Article

References (36)

1. I. Urushizaki 1990 Side effects by anticancer drugs and their treatments Jpn J Cancer Chemother 17 1959 1969 1:STN:280:DyaK3czmsFGnuw%3D%3D
2. K.R. Merrifield B.J. Chaffee 1989 Recent advances in the management of nausea and vomiting caused by antineoplastic agents Clin Pharm 8 187 199 1:STN:280:DyaL1M3gvFGrug%3D%3D 2650957
3. J. Laszlo 1983 Nausea and vomiting as major complications of cancer chemotherapy Drugs 25 Suppl1 1 7 10.2165/00003495-198300251-00002 6840017
4. A. Coates S. Abraham S.B. Kaye, et al. 1983 On the receiving end-patient perception of the side-effects of cancer chemotherapy Eur J Cancer Clin Oncol 19 203 208 10.1016/0277-5379(83)90418-2 1:STN:280:DyaL3s7jtFyitw%3D%3D 6681766 (Pubitemid 13155858)
5. R.A. Joss B.C. Brand K.S. Buser, et al. 1990 The symptomatic control of cytostatic drug-induced emesis. A recent history and review Eur J Cancer 26 Suppl1 2 8
6. K.S. Sridhar E. Donnelly 1988 Combination antiemetics for cisplatin chemotherapy Cancer 61 1508 1517 10.1002/1097-0142(19880415)61:8<1508::AID- CNCR2820610806>3.0.CO;2-H 1:STN:280:DyaL1c7msVOjsQ%3D%3D 3280112
7. P.L.R. Andrews W.G. Rapeport G.J. Sanger 1988 Neuropharmacology of emesis induced by anti-cancer therapy Trends Pharmacol Sci 9 334 341 10.1016/0165-6147(88)90106-X 1:STN:280:DyaK3c7hslOksQ%3D%3D 3078093 (Pubitemid 18227801)
8. F. Mitchelson 1992 Pharmacological agents affecting emesis Drugs 43 295 315 10.2165/00003495-199243030-00002 1:CAS:528:DyaK38Xit1Ontbw%3D 1374316
9. L.X. Cubeddu I.S. Hoffmann N.T. Fuenmayor, et al. 1990 Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting N Engl J Med 322 810 816 1:STN:280:DyaK3c7nsVaguw%3D%3D 1689807
10. P.V. Tortorice M.B. O'Connell 1990 Management of chemotherapy-induced nausea and vomiting Pharmacotherapy 10 129 145 1:STN:280:DyaK3c3nt1Gjsw%3D%3D 2190193
11. 3 receptor antagonists in cancer patients Cancer Chemother Pharmacol 54 185 190 10.1007/s00280-004-0798-x 1:CAS:528:DC%2BD2cXlt1Gks7c%3D 15168080
12. 3 receptor antagonist: correlation with anti-emetic response Cancer Chemother Pharmacol 24 45 49 10.1007/BF00254104 1:STN:280:DyaL1M3kvFKnsg%3D%3D 2541937
13. Interview form, azasetron hydrochloride (2000) Japan Tobacco, Tokyo
14. M. Sakamori S. Takehara M. Setoguchi 1992 High affinity binding of Y-25130 for serotonin 3 receptor Folia Pharmacol Jpn 100 137 142 1:CAS:528:DyaK38Xlt1Churk%3D
15. Interview form, indisetron hydrochloride (2005) Yakult Honsha, Tokyo
16. T. Yamada T. Tadokoro F. Nakata, et al. 2004 Pharmacokinetics and safety of indisetron tablets in healthy subjects. Single oral dose study Jpn Pharmacol Ther 32 807 813 1:CAS:528:DC%2BD2MXls1GktQ%3D%3D (Pubitemid 40874571)
17. 3 receptor antagonist Jpn Pharmacol Ther 32 789 797 1:CAS:528: DC%2BD2MXls1Gktw%3D%3D
18. Interview form, ondansetron hydrochloride (2005) GlaxoSmith-Kline, Tokyo
19. Interview form, granisetron hydrochloride (2006) Chugai Pharmaceutical, Tokyo
20. R.E. Haddock F.C. Hidham J.A. Pope, et al. 1990 Kinetics of granisetron hydrochloride-distribution, metabolism and excretion in rats and dogs following intravenous administration Clin Rep 24 6821 6843
21. Interview form, ramosetron hydrochloride (2006) Astellas Pharma, Tokyo
22. Y. Kawabata H. Sakiyama S. Muto, et al. 1994 Clinical evaluation and pharmacokinetics of YM060 against the nausea and vomiting induced by anti-cancer drug-phase III clinical study Nishinihon J Urol 56 1445 1456
23. 3 receptor antagonist, YM060, YM114 (KAE-393), granisetron and ondansetron in rat vagus nerve and cerebral cortex Neuropharmacology 34 631 637 10.1016/0028-3908(95)00033-3 1:CAS:528: DyaK2MXmvFygurc%3D 7566499
24. Interview form, tropisetron hydrochloride (2005) Novartis Pharma, Tokyo
25. C.R. Lee G.L. Plosker D. McTavish 1993 Tropisetron: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as an antiemetic Drugs 46 925 943 10.2165/00003495-199346050-00009 1:STN:280:DyaK2c7hs1Clsw%3D%3D 7507039
26. 3 receptor Neurochem Int 23 373 383 10.1016/0197-0186(93) 90081-F 1:CAS:528:DyaK3sXms1Gms7k%3D 8220179
27. E. Hoshino Y. Ono S. Oshiba, et al. 1996 Phase I study of azasetron hydrochloride (Y-25130) tablet. Single dose and multiple dose studies J Clin Ther Med 12 2483 2501
28. Y. Kumagai S. Nakajima T. Kotegawa, et al. 1992 Phase I study of ondansetron (the first report). Single and multiple oral dose studies in healthy male volunteers J Clin Ther Med 8 1495 1504
29. S. Kudo H. Igarashi T. Hayami, et al. 1996 Biological equivalence study of 2 mg and 1 mg tablets of granisetron hydrochloride Jpn Pharmacol Ther 24 1529 1535
30. S. Nomiyama T. Tanaka N. Masuda, et al. 1997 Phase I study of tropisetron capsules in healthy volunteers-single administration Clin Rep 29 1523 1559
31. M. Nakajima M. Kanemaru Y. Miura, et al. 1994 Phase I study of YM060 tablets in healthy subjects. Single intravenous dose study Jpn J Clin Exp Med 71 2461 2468
32. 3 receptor antagonist. Single intravenous administration Clin Rep 26 2535 2547
33. Y. Kumagai S. Nakajima T. Kotegawa, et al. 1992 Phase I study of ondansetron (the second report). Single intraavenous dose study and continuous drip infusion dose study in healthy volunteers J Clin Ther Med 8 1505 1513
34. H. Kumakura J. Koyanagi Y. Nishioka, et al. 1990 Phase I study of granisetron (second report). Pharmacokinetics of granisetron following single and repeat intravenous drip infusion in Japanese healthy volunteers J Clin Ther Med 6 Suppl5 25 34
35. M. Nakajima M. Kanemaru Y. Miura, et al. 1995 Phase I study of YM060 tablets Jpn J Clin Exp Med 72 264 278
36. 3 receptor occupancy of serotonin Yakugaku Zasshi 127 353 357 10.1248/yakushi.127.353 1:CAS:528:DC%2BD2sXktVSls7g%3D 17268155 (Pubitemid 46203278)